Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cancer Discov. 2021 Feb 9;11(7):1661–1671. doi: 10.1158/2159-8290.CD-20-0896

Figure 4: GM18 improves the effector function of HER2-CAR T-cells.

Figure 4:

(A) Transduction efficiency of HER2-CAR and GM18 in human T-cells as measured by flow analysis for the GM-CSFR alpha chain (anti-CD116) and CAR (anti-murine F(ab’)2). NT: non-transduced. NT and GM18 T-cells (N=3 different donors); CAR and CAR.GM18 T-cells (N=6 different donors). (B) Fold expansion of HER2-CAR and HER2-CAR.GM18 T-cells following serial coculture with LM7 tumor cells weekly and IL-15 (N=4 different donors; panels 1-3 unsorted T-cells, panel 4 sorted T-cells). (C) Expansion from 1st to 4th simulation; p=0.0149; paired t-test. (D) Quantification of cytokine production by CAR T-cells after one stimulation with LM7 tumor cells. (E) Cytokine production by HER2-CAR and HER2-CAR.GM18 T-cells after repeat stimulations; double gradient heatmap (yellow: 100 pg/mL, white: 102 pg/mL, blue 106 pg/mL). (F) NSG mice were injected with 1x106 LM7-ffLuc i.p. followed by i.v CAR T-cells on day 7 (N=5 per group, 1 donor). (G) Bioluminescence analysis of total flux in LM7-ffLuc tumor-bearing mice. (H) Comparison of tumor burden as measured by total flux at different time points. Tumor only vs 1x105 or 3x105 HER2-CAR.GM18 T-cells; Xp=0.0017, #p<0.0001; two-way ANOVA. (I) Kaplan-Meier survival curve; *p=0.0132, **p=0.0018, Log-rank (Mantel-Cox) test.